Daily weight-loss tablets are widening access to GLP-1 treatments and reshaping the industry.
Analysts expect the market to reach about $200bn by the early 2030s.
Novo Nordisk launched the first oral Wegovy in the US, with prescriptions rising rapidly.
Patients say pills are easier than injections, cheaper and simpler to store.
Many people are switching after insurance changes or needle fatigue.
Rival Eli Lilly plans to release its own tablet, orforglipron, soon.
The growing competition is expected to bring more users into treatment.
Pills will likely attract overweight patients, while injections remain more effective for major weight loss.
Limited public funding, high prices and side-effects still restrict access.
However, falling costs and wider insurance coverage are increasing demand.
With global obesity rising quickly, drugmakers see tablets as the next major growth phase.
